Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 42 от 222

Набира участници

Visual Influences on Vestibular Adaptation

Vestibular Hypofunction Binocular Vision Abnormalities Reduced Vision

The goal of this study is to learn whether a balance-training exercise called incremental vestibulo-ocular reflex adaptation (IVA) is safe and effective for adults with vision impairments, with or without additional vestibular (inner-ear balance) problems. The main questions it aims to answer are: * Does IVA cause only mild, temporary symptoms and no serious adverse events? * Does IVA improve eye-movement reflexes, balance, and walking, and do these improvements differ between people with vision problems alone and those with both vision and vestibular impairments? Researchers will compare adults with vision impairment only to adults who have both vision and vestibular impairments to see whether the groups respond differently to IVA. Participants will: * Complete symptom ratings before and after IVA * Undergo tests of vestibular reflexes (e.g., VOR gain) * Complete balance and walking assessments

Начало: 04.02.2026 Край: 01.12.2029 Възраст: 18–60 г.

United States Emory University NCT07380256

Набира участници Фаза 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

Healthy Participants

This is a Phase 1, double-blind, sponsor-unblinded, randomized, placebo-controlled study designed to characterize the safety, tolerability, and PK of JZP047 in healthy participants following single-ascending doses of study intervention. Additionally, the effect of food on PK following a single dose of JZP047 will be assessed through comparison of PK between the fed and fasted states.

Начало: 03.02.2026 Край: 05.07.2026 Възраст: 18–55 г.

United States Jazz Pharmaceuticals NCT07377539

Набира участници Фаза 3

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Gastric Cancer Gastroesophageal Junction Adenocarcinoma Esophageal Cancer

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Начало: 03.02.2026 Край: 27.10.2031 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +18 AstraZeneca NCT07431281

Набира участници

Perineural Dextrose Versus Local Anesthetic Injections in Knee Osteoarthritis

Knee Osteoarthritis

This prospective observational study aims to compare the clinical effectiveness of perineural 5% dextrose injections and perineural local anesthetic injections in patients with symptomatic knee osteoarthritis. Adult patients receiving routine perineural injection therapy will be followed for six months. Pain intensity and functional outcomes will be assessed at baseline and at 1, 3, and 6 months after treatment using validated clinical assessment tools.

Начало: 02.02.2026 Край: 01.08.2026 Възраст: 40–65 г.

Turkey (Türkiye) Ankara Training and Research Hospital NCT07381621

Набира участници

Home Treatment of Patients With Active Cancer and Acute Pulmonary Embolism Without HESTIA Criteria.

Active Cancer and Symptomatic or Incidental Pulmonary Embolism Without HESTIA Criteria

Main objective of this multisite randomised study aims to demonstrate in patients with active cancer and symptomatic or incidental PE without HESTIA criteria, that home treatment is non-inferior to hospitalisation as regards the 14-day rate of the composite primary endpoint. Primary endpoint corresponds to the rate of the composite of centrally adjudicated recurrent incidental or symptomatic VTE (i.e. non fatal or fatal PE, proximal and/or distal deep venous thrombosis (DVT) of lower limb or upper limb or catheter-related thrombosis), major or clinically relevant non-major bleeding and all-cause death within 14 days following randomisation. This composite endpoint represents the net clinical benefit of outpatient care. Included patients will be randomised into two groups and stratified according to symptomatic or incidental PE, site of cancer, localised or metastatic cancer and centre. Patients randomised to the home-treatment group will be discharged home within 24hrs after randomisation. Patients will be contacted by the local thrombosis team by phone within 7 days following inclusion. Patients randomised to the hospitalisation group will be admitted in the hospital during at least 48hrs after randomisation. After this time, physicians in charge of the patients will be free to discharge the patients.

Начало: 02.02.2026 Край: 01.04.2029 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT07315347

Набира участници Фаза 2/3

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Agitation Associated With Alzheimer's Disease Dementia

The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

Начало: 02.02.2026 Край: 01.02.2029 Възраст: 55–90 г.

Canada, United Kingdom, United States Exciva GmbH NCT07284472

Набира участници Фаза 2

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Overweight Obesity

The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.

Начало: 02.02.2026 Край: 18.02.2027 Възраст: 18–65 г.

Canada, United States Novo Nordisk A/S NCT07395687

Набира участници

A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke

Ischemic Stroke

The purpose of this study is to assess the safety and the effectiveness of the Adaptive Tip Catheter (ATC) used as a first line direct aspiration thrombectomy technique for patients suffering of an acute ischemic stroke.

Начало: 02.02.2026 Край: 31.07.2027 Възраст: 18–90 г.

Belgium, France, Germany +2 Neuravi Limited NCT07367100

Набира участници

Exploration of the Effect of a Wheat Polar Lipid Complex on Vaginal Dryness in Healthy Postmenopausal Women

Vaginal Dryness Menopause Symptoms

This study aims to explore the positive effect of a dietary supplement composed of wheat polar lipids on vaginal dryness in healthy postmenopausal women

Начало: 02.02.2026 Край: 01.11.2026 Възраст: 45–65 г.

Belgium Seppic NCT07386249

Набира участници Фаза 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)

Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by progressive fibrosis (scarring) of the lungs. As the disease progresses, patients experience loss of lung function and increased breathing problems. LTI-03 is hypothesized to treat IPF by protecting and restoring the function of the oxygen uptake cells and by controlling lung fibrosis which may result in improving lung scarring. The purpose of this research is to evaluate LTI-03 including: its safety, whether it causes side effects, whether it improves lung scarring, and whether it improves IPF symptoms. LTI-03 will be compared to placebo in patients diagnosed with IPF within the last 5 years. Patients on a stable dose of nintedanib, pirfenidone, or nerandomilast (if available by prescription) may participate. Trial Design: This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study that includes a 28-day Screening Period, a 24-week Treatment Period, and 4-week Follow-up Period. Study Assessments: Up to 9 visits to the study clinic will be required. Safety and tolerability will be evaluated with the following assessments: physical examination; collection of vital sign data (heart rate, blood pressure, respiratory rate and peripheral oxygen saturation \[SpO2\] via pulse oximetry); heart data collected by 12-lead electrocardiogram; and collection of blood samples for safety laboratory tests. In addition, participants will be asked about any adverse events (side effects) they have experienced between clinic visits, if they have changed any medications, and if they are able to properly use their study drug inhaler. Participants will undergo a lung function test (spirometry) at every visit, which will be used to evaluate both safety and efficacy. Another test measuring the diffusion capacity of the lungs for carbon monoxide (DLCO) will be required at Screening only. Blood samples will also be collected at each visit to measure disease biomarkers. At select visits patients will be asked to complete the Living with Pulmonary Fibrosis questionnaire to evaluate their IPF symptoms. Participants will also undergo a specialized lung scan (HRCT) at Baseline and at the End of Treatment to measure changes in lung fibrosis. Interventions: LTI-03 and placebo are provided in powder-filled capsules that participants will self- administer using an inhaler. Placebo capsules look like LTI-03 capsules but have no active ingredients. Approximately 120 participants will be randomly assigned in a blinded manner to one of study drug treatment groups.

Начало: 02.02.2026 Край: 31.12.2027 Възраст: от 40 г. Лечение

Australia, Poland, United States Rein Therapeutics NCT06968845

Набира участници

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus

The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5 in people with diabetes. The study will include people with Type 1 diabetes who are 7-85 years old and people with Type 2 diabetes who are 18-85 years old. Patients will use their current therapy while also wearing the DS5 for up to 40 days. During this time, they will complete a meal and exercise log. Patients will then be put into one of three groups by a computer by chance and given the NMX8 pump to use for 90 days. During this time, patients will either bolus or not bolus for meals and continue to complete a meal and exercise log depending on the group they are in. Once their part in the study is over, if patients like the pump and want to keep using it, they may be able to join a Continued Access Period to keep using the NMX8 pump.

Начало: 02.02.2026 Край: 01.12.2026 Възраст: 7–85 г. Друго

Australia, New Zealand, United States Medtronic MiniMed, Inc. NCT07228117

Набира участници Фаза 1/2

Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear cell RCC that has progressed after standard therapy. The study is designed to determine a recommended dose and schedule, characterize hepatobiliary safety, and explore whether CD70-high, CAIX-high, or dual-high tumors derive the greatest benefit. Biomarker-defined activity signals will be used to guide whether later development should prioritize CD70, CAIX/CA9, or continued dual-targeting.

Начало: 02.02.2026 Край: 17.04.2028 Възраст: от 18 г.

China Beijing Biotech NCT07551349

Набира участници

A Clinical Cohort Registry Study on Primary PCI for Acute Myocardial Infarction at Zhongshan Hospital

Acute Myocardial Infarction (AMI)

This study is a registry-based cohort investigation, prospectively enrolling patients who were diagnosed with acute myocardial infarction and underwent primary percutaneous coronary intervention (PCI) at Zhongshan Hospital, Fudan University, between January 1, 2009, and December 31, 2028. Baseline clinical characteristics, procedural details, laboratory results, and medication records will be systematically collected and documented. The clinical follow-up will encompass both in-hospital monitoring and post-discharge surveillance extending up to two years after the procedure.

Начало: 01.02.2026 Край: 31.12.2030

China Shanghai Zhongshan Hospital NCT07400601

Набира участници Фаза 1

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Uveal Melanoma, Metastatic

This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib

Начало: 01.02.2026 Край: 01.12.2029 Възраст: от 18 г. Лечение

Australia St Vincent's Hospital, Sydney NCT07203391

Набира участници

Clear Orthodontic Expander Versus Hyrax

Malocclusion Narrow Maxilla

This study will be conducted to evaluate the effectiveness of a clear expander fabricated from 2-mm biocompatible polyethylene terephthalate glycol (PETG) thermoforming material integrated with an expansion screw in achieving dental and skeletal expansion in adolescent patients, compared with the conventional Hyrax expander.

Начало: 01.02.2026 Край: 01.02.2027 Възраст: 10–14 г.

Iraq University of Baghdad NCT07362160

Набира участници Фаза 2

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NSCLC Stage IV EGFR Gene Mutation

Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.

Начало: 01.02.2026 Край: 22.01.2028 Възраст: 18–75 г.

China Tianjin Medical University Cancer Institute and Hospita NCT07548060

Набира участници

iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults

Healthy Aging Anti Aging

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.

Начало: 01.02.2026 Край: 01.01.2027 Възраст: 40–75 г.

United States Synbiotic Health NCT07407894

Набира участници Фаза 2

Study to Evaluate the REMEDY SPECTRUM IM Spacer Nail in the Treatment of Ankle-Related Infections

Periprosthetic Joint Infection

This study is being conducted to evaluate the safety and effectiveness of the REMEDY SPECTRUM IM Spacer Nail in the treatment of ankle-related infections. The study is expected to take approximately 18 months from first subject enrolled to the last follow-up visit. It will have a 12-month enrollment period and a 6-month follow-up. This study is a Prospective, multicenter, single-arm clinical trial. All subjects enrolled in this study will receive the REMEDY SPECTRUM IM Spacer Nail.

Начало: 01.02.2026 Край: 01.12.2027 Възраст: от 21 г.

United States OsteoRemedies, LLC NCT06428448

Набира участници

Comparative Study of CPAP Predictive Equations and In-laboratory Manual Titration in Thai Patients With Obstructive Sleep Apnea

OSA - Obstructive Sleep Apnea

The goal of this observational study is to compare predictive equations for continuous positive airway pressure (CPAP) with in-laboratory manual titration in patients with obstructive sleep apnea (OSA). The main question the study aims to answer is: Which CPAP predictive equation best predicts the optimal CPAP pressure in OSA patients in Thailand? Participants will undergo an in-laboratory sleep study.

Начало: 01.02.2026 Край: 31.12.2026 Възраст: от 18 г.

Thailand Thammasat University NCT07376343

Набира участници

Remission in Adults With Mild-to-moderate Asthma in Thailand

Asthma Mild-to-moderate Asthma Asthma Control Level

The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand. The main question the study aims to answer is: What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.

Начало: 01.02.2026 Край: 31.12.2026 Възраст: от 18 г.

Thailand Thammasat University NCT07351916

1 … 40 41 42 43 44 … 222